Quality Use of Generic Medicines

The provision of healthcare has traditionally been managed based on the philosophy that, where the patient is concerned, price should not be a hindrance. However, with the global escalating healthcare cost, governments in many countries have adopted ongoing series of cost containment attempts in an effort to spend their limited financial resources efficiently so that equitable access to healthcare can be provided. One of the many ways to control healthcare expenditure is to promote the use of cheaper generic drugs instead of the more expensive branded equivalents and this strategy had been adopted by health authorities in many countries around the globe. The availability of cheaper generic medicines in the global market gives an opportunity for both the government and consumers alike to reduce the cost associated with the use of pharmaceutical products. However, the use of generic medicines is often seen as a contentious issue among majority of consumers and healthcare professionals. This book will give an insight from the Australian persepctive on the improving quality use of generic medicines among population.

[1]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[2]  D. Ames,et al.  Hyponatraemia in elderly psychiatric patients treated with Selective Serotonin Reuptake Inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit , 2002, International journal of geriatric psychiatry.

[3]  A. Kjaer,et al.  Serotonin Receptors Involved in Vasopressin and Oxytocin Secretion , 2003, Journal of neuroendocrinology.

[4]  N. Chapman,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[5]  S. Myers Interactions between complementary medicines and warfarin , 2002 .

[6]  A. Laupacis,et al.  Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. , 1999, Archives of internal medicine.

[7]  S. West,et al.  Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study , 2002 .

[8]  P. Phillips Insulins in 2002 , 2002 .

[9]  A. Gallus,et al.  Managing warfarin therapy in the community , 2001 .

[10]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[11]  S. Faraone,et al.  Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. , 1998, The American journal of psychiatry.

[12]  L. Ryysy,et al.  Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[13]  M. Gent,et al.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[14]  K. Parhofer,et al.  Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. , 2001, The American journal of cardiology.

[15]  P. Froom,et al.  Oral anticoagulants in the elderly , 2003, British journal of haematology.

[16]  D. Sherman,et al.  The secondary prevention of stroke in patients with atrial fibrillation. , 1986, Archives of neurology.

[17]  Donald J. Birkett,et al.  Generics - equal or not? , 2003 .

[18]  T. Dunning Insulin delivery devices , 2002 .

[19]  P. Wolf,et al.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke , 1978, Neurology.

[20]  J. Vandenbroucke,et al.  Assessment of a Bleeding Risk Index in Two Cohorts of Patients Treated with Oral Anticoagulants , 1996, Thrombosis and Haemostasis.

[21]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[22]  J. Wernicke,et al.  Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. , 2001, Pediatrics.

[23]  O. Spigset,et al.  Hyponatremia in Relation to Treatment with Antidepressants: A Survey of Reports in the World Health Organization Data Base for Spontaneous Reporting of Adverse Drug Reactions , 1997, Pharmacotherapy.

[24]  Panos Kanavos,et al.  Encouraging the use of generic medicines: implications for transition economies. , 2002, Croatian medical journal.

[25]  G. McColl,et al.  Experimental and clinical pharmacology : Tumour necrosis factor alpha inhibitors for the treatment of adult rheumatoid arthritis , 2004 .

[26]  K. Pile,et al.  Disease modifying drugs in adult rheumatoid arthritis , 2003 .

[27]  M. Hochberg,et al.  Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[28]  S. West,et al.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies , 2003, Biological Psychiatry.

[29]  A. Laupacis,et al.  Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. , 2002, Archives of internal medicine.

[30]  L Goldman,et al.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. , 1989, The American journal of medicine.

[31]  D. Reda,et al.  Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. , 2000, Archives of internal medicine.

[32]  L. Joosten,et al.  Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation , 2002, Annals of the rheumatic diseases.

[33]  J. Peláez de Loño [Generic medicines]. , 1999, Revista de enfermeria.

[34]  G. Raskob,et al.  Hemorrhagic complications of anticoagulant treatment. , 1992, Chest.

[35]  J. Hirsh,et al.  Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. , 2000, Archives of internal medicine.

[36]  J. Biederman,et al.  Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[37]  Yuchiao Chang,et al.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.

[38]  J. Després,et al.  Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial , 2002, Journal of internal medicine.

[39]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[40]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[41]  P. Ridker,et al.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[42]  L. Vanhaelst,et al.  Comparison of Micronized Fenofibrate and Pravastatin in Patients With Primary Hyperlipidemia , 2003, Journal of cardiovascular pharmacology.

[43]  K. Kaye Trouble with tramadol , 2004 .

[44]  W. Gulliver,et al.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. , 2002, Journal of the American Academy of Dermatology.